Imbruvica Shows Response in 2/3 of Steroid Dependent, Refractory cGVHD Patients in Phase II Study December 22, 2016Vol.39 No.11
Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease December 22, 2016Vol.39 No.11
Drugs & Targets Keytruda becomes first anti-PD-1 therapy to receive a CHMP positive opinion for previously untreated NSCLC December 16, 2016Vol.42 No.46
Obama Signs Cures Act, Funding Biden’s Moonshot and Boosting NIH, NCI, FDA Budgets Over 10 Years December 16, 2016Vol.42 No.46By Matthew Bin Han Ong
Hackensack Cancer Center, MSKCC Form Business, Clinical Partnership in New Jersey December 16, 2016Vol.42 No.46By Paul Goldberg
Drugs & Targets Verastem licenses exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib. December 11, 2016Vol.42 No.42
